If you spend money each month on anti-aging supplements, a large new analysis from Yale University has findings worth reading. Researchers reviewed 51 clinical studies and found the interventions that consistently moved biological age markers were prescription drugs and structured lifestyle changes. The pills lining most pharmacy shelves were not among them.
What the 51-Study Nature Medicine Analysis Tested
A team at Yale School of Medicine published the analysis in Nature Medicine on August 21, 2026. Lead author Raghav Sehgal and senior author Albert Higgins-Chen are based in the Department of Psychiatry at Yale School of Medicine. They also hold affiliations in the Program in Computational Biology and Bioinformatics and the Program in Pathology at Yale. The full team includes Daniel Borrus, Jenel F. Armstrong, John Gonzalez, Jessica Kasamoto, Yaroslav Markov, Ahana Priyanka, Ryan Smith, Natàlia Carreras-Gallo, Jessica Lasky-Su, Varun B. Dwaraka, and Michael J. Corley.
The dataset covered 16 prominent epigenetic clocks and 94 additional DNA methylation biomarkers—more than 110 in total—across 51 studies. Epigenetic clocks measure chemical tags on DNA—called methylation marks—that shift as the body ages. They produce a “biological age” reading that can differ from a person’s actual age. A 52-year-old whose biological age tests at 46 looks younger at the cellular level, though that gap alone doesn’t guarantee more years ahead.
The team sorted every intervention from those 51 studies into four groups: prescription medications, lifestyle changes, over-the-counter supplements, and medical procedures. Then they compared how well each moved the clock readings.
A Yale University analysis of 51 clinical studies in Nature Medicine found that prescription drugs consistently lowered DNA-based biological age markers. Those drugs included metformin, semaglutide, and anti-TNF therapies. Lifestyle interventions including dietary and exercise approaches also lowered them. Popular over-the-counter anti-aging supplements showed little measurable effect. Researchers caution that biomarker drops do not yet prove longer human lifespans.
What Moved the Numbers: Prescription Drugs and Lifestyle Change
Anti-TNF drugs and metformin showed consistent reductions in biological age markers across the reviewed studies. Semaglutide is among the pharmacological interventions studied in the dataset. Metformin is a decades-old diabetes medication already under investigation for longevity uses. Semaglutide is the active compound in GLP-1 receptor agonist medications now widely prescribed for type 2 diabetes and weight management. Anti-TNF drugs treat inflammatory conditions such as rheumatoid arthritis and IBD by blocking tumor necrosis factor, a protein involved in systemic inflammation.
Research on poor blood sugar control in type 2 diabetes and its effect on immune function helps explain why metabolic drugs may carry benefits. Those benefits reach well beyond glucose management. All three drug classes operate on biological processes. Those processes—inflammation, insulin signaling, metabolic regulation—are directly linked to how the body ages at a cellular level.
Lifestyle interventions, including both dietary and exercise approaches, produced meaningful results as a category. Among the dietary interventions in the dataset, Mediterranean, low-fat, and low-carbohydrate diets were studied and showed effects on epigenetic biomarkers. The Mediterranean diet showed particularly replicable effects, with two variants producing consistent results in healthy cohorts. No single diet type stood clearly above the others.
That matters for anyone trying to slow biological aging without a prescription. The analysis points to lifestyle intervention as a meaningful category, with both dietary and exercise approaches contributing to the effect.
Why Over-the-Counter Supplements Fell Short
This is where the results diverge most sharply from common marketing claims. Across all 51 studies, over-the-counter anti-aging supplements showed little measurable effect on epigenetic clock readings. The category as a whole did not perform at the level of the prescription drug or lifestyle groups.
That gap is worth sitting with. Metformin and semaglutide require a physician. Anti-TNF therapies are used for autoimmune conditions such as rheumatoid arthritis and IBD. The interventions that moved biological age biomarkers most reliably are not available over a counter. Karmactive’s earlier reporting covered how Damon Wayans Sr. managed a type 2 diabetes diagnosis and the downstream metabolic risks that follow. It speaks to why early medical management of metabolic conditions may carry more weight than supplement use.
The analysis also found something that may seem counterintuitive. People living with existing diseases generally saw larger biological age reductions than healthy participants did. That likely reflects the fact that disease-driven biological aging gives interventions more room to work. A person already running a higher biological age has further to come back down. Epigenetic clocks trained to predict mortality or pace of aging showed the strongest responses across the 51 studies. Biomarkers trained in older or more clinically diverse cohorts tended to be more sensitive.
What a Lower Biological Age Reading Does—and Doesn’t—Mean
Senior author Albert Higgins-Chen made the lifespan caveat explicit. A lower reading on an epigenetic clock is a biomarker shift. It is not proof of a longer human lifespan. The clocks measure DNA methylation patterns associated with aging. No study has yet shown that moving those numbers extends how long a person actually lives.
That distinction matters. It doesn’t make the findings useless. These biomarkers are among the best tools researchers currently have for measuring what interventions do to the aging process at a molecular level. But a person who improves their epigenetic age score has not been shown to have added years to their life. That evidence does not yet exist.
The analysis is published in Nature Medicine, DOI: 10.1038/s41591-026-04562-9. The dataset of 51 studies covers more than 110 biomarkers and 16 prominent epigenetic clocks. The researchers say the next step is studies that link these biomarker shifts directly to health outcomes and lifespan data.